Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Amgen Ventures

Founders Leroy Hood Marvin Caruthers

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 111
Average round size
info
The average size of a deal this fund participated in
$49M
Portfolio companies 72
Rounds per year 5.55
Lead investments 7
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.33
Exits 27
Key employees 1
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

In 2004 was created Amgen Ventures, which is appeared as VC. The main department of described VC is located in the San Francisco. The fund was located in North America if to be more exact in United States.

The fund was created by Leroy Hood, Marvin Caruthers. Besides them, we counted 1 critical employee of this fund in our database.

Among the most popular fund investment industries, there are Health Care, Biopharma. Among the most popular portfolio startups of the fund, we may highlight Alector, TetraLogic Pharmaceuticals, Senti Biosciences. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

The typical case for the fund is to invest in rounds with 6-7 participants. Despite the Amgen Ventures, startups are often financed by Alta Partners, SV Health Investors, ARCH Venture Partners. The meaningful sponsors for the fund in investment in the same round are OVP Venture Partners, HealthCare Ventures, Alta Partners. In the next rounds fund is usually obtained by HealthCare Ventures, Alta Partners, Remeditex Ventures.

This Amgen Ventures works on 1 percentage points less the average amount of lead investments comparing to the other organizations. The typical startup value when the investment from Amgen Ventures is 100-500 millions dollars. Considering the real fund results, this VC is 11 percentage points less often commits exit comparing to other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2014. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 investment rounds annually.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Amgen Ventures:
Typical Co-investors
Amgen Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Amgen Ventures:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Mindset Medical

Health Care
Hospital
Information Technology
06 Jun 2024 Phoenix, Arizona, United States

Enlaza Therapeutics

Biopharma
Biotechnology
Health Care
Therapeutics
$100M30 Apr 2024 La Jolla, California, United States

Culmination Bio

Biotechnology
Health Care
$10M30 Nov 2023 -

Feldan Therapeutics

Biotechnology
Therapeutics
$16M13 Jun 2023 Quebec City, Quebec, Canada

Casma Therapeutics

Biotechnology
Health Care
Therapeutics
$46M15 Nov 2022 Cambridge, Massachusetts, United States

Inversago Pharma

Biopharma
Biotechnology
Health Care
Medical
Pharmaceutical
$75M17 Oct 2022 Montreal, Quebec, Canada

BigHat Biosciences

Artificial Intelligence
Biotechnology
Medical
Therapeutics
$75M20 Jul 2022 California, United States

Kernal Biologics

Biotechnology
Pharmaceutical
Therapeutics
$25M07 Jul 2022 Cambridge, Massachusetts, United States

ReCode Therapeutics

Biopharma
Biotechnology
Health Care
Pharmaceutical
Wellness
$120M29 Jun 2022 Dallas, Texas, United States
News
Carlyle and Leading Healthcare-Focused Venture Funds Announce Strategic Growth Investment of up to $430 Million in Saama

– Saama technologies announced a strategic growth investment and will be acquired by Carlyle.
– Saama’s intelligent Life Science Analytics Cloud (LSAC) is used by over 50 pharma and biotech companies on more than 1,500 studies.
– As an end-to-end platform, LSAC provides a unified approach to clinical trial data management and analytics.
– Carlyle has made a strategic growth investment and will acquire a majority stake in the Company.
– A broad co-investor group with several healthcare-focused venture funds, including Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners, will be investing alongside Carlyle.

Obsidian Therapeutics Closes $115M Series B Financing

– Obsidian Therapeutics, Inc. is a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies.
– The company closed a $115m Series B financing.
– The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital, and existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb.
– Proceeds from the financing will be used to drive Obsidian’s lead tumor infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma. In addition, the company plans to rapidly expand cytoTIL15 into multiple other solid tumor types and to advance its commercial manufacturing build.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Amgen Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 111
Average round size 49M
Rounds per year 5.55
Peak activity year 2022
Lead investments 7
Follow on index 0.33
Exits 27
Group Appearance index 0.98

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Mindset Medical

Health Care
Hospital
Information Technology
06 Jun 2024 Phoenix, Arizona, United States

Enlaza Therapeutics

Biopharma
Biotechnology
Health Care
Therapeutics
$100M30 Apr 2024 La Jolla, California, United States

Culmination Bio

Biotechnology
Health Care
$10M30 Nov 2023 -

Feldan Therapeutics

Biotechnology
Therapeutics
$16M13 Jun 2023 Quebec City, Quebec, Canada

Casma Therapeutics

Biotechnology
Health Care
Therapeutics
$46M15 Nov 2022 Cambridge, Massachusetts, United States

Inversago Pharma

Biopharma
Biotechnology
Health Care
Medical
Pharmaceutical
$75M17 Oct 2022 Montreal, Quebec, Canada

BigHat Biosciences

Artificial Intelligence
Biotechnology
Medical
Therapeutics
$75M20 Jul 2022 California, United States

Kernal Biologics

Biotechnology
Pharmaceutical
Therapeutics
$25M07 Jul 2022 Cambridge, Massachusetts, United States

ReCode Therapeutics

Biopharma
Biotechnology
Health Care
Pharmaceutical
Wellness
$120M29 Jun 2022 Dallas, Texas, United States
Crunchbase icon

Content report

The following text will be sent to our editors: